1. Home
  2. INSM vs EQT Comparison

INSM vs EQT Comparison

Compare INSM & EQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • EQT
  • Stock Information
  • Founded
  • INSM 1988
  • EQT 1925
  • Country
  • INSM United States
  • EQT United States
  • Employees
  • INSM N/A
  • EQT N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • EQT Oil & Gas Production
  • Sector
  • INSM Health Care
  • EQT Energy
  • Exchange
  • INSM Nasdaq
  • EQT Nasdaq
  • Market Cap
  • INSM 29.0B
  • EQT 33.9B
  • IPO Year
  • INSM 2000
  • EQT N/A
  • Fundamental
  • Price
  • INSM $162.43
  • EQT $56.67
  • Analyst Decision
  • INSM Strong Buy
  • EQT Buy
  • Analyst Count
  • INSM 19
  • EQT 20
  • Target Price
  • INSM $152.71
  • EQT $62.60
  • AVG Volume (30 Days)
  • INSM 2.2M
  • EQT 10.1M
  • Earning Date
  • INSM 10-30-2025
  • EQT 10-21-2025
  • Dividend Yield
  • INSM N/A
  • EQT 1.12%
  • EPS Growth
  • INSM N/A
  • EQT 20.64
  • EPS
  • INSM N/A
  • EQT 1.92
  • Revenue
  • INSM $398,105,000.00
  • EQT $7,103,623,000.00
  • Revenue This Year
  • INSM $32.44
  • EQT $69.06
  • Revenue Next Year
  • INSM $123.99
  • EQT $17.40
  • P/E Ratio
  • INSM N/A
  • EQT $29.31
  • Revenue Growth
  • INSM 21.15
  • EQT 60.31
  • 52 Week Low
  • INSM $60.40
  • EQT $35.45
  • 52 Week High
  • INSM $163.22
  • EQT $61.02
  • Technical
  • Relative Strength Index (RSI)
  • INSM 80.62
  • EQT 64.98
  • Support Level
  • INSM $156.87
  • EQT $55.55
  • Resistance Level
  • INSM $163.22
  • EQT $57.55
  • Average True Range (ATR)
  • INSM 4.29
  • EQT 1.70
  • MACD
  • INSM 0.73
  • EQT 0.43
  • Stochastic Oscillator
  • INSM 94.51
  • EQT 90.39

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About EQT EQT Corporation

EQT is an independent natural gas production company. It focuses its operations in the cores of the Marcellus and Utica shales, located in the Appalachian Basin in the Eastern United States. Its main customers include marketers, utilities, and industrial operators in the Appalachian Basin. The company has three reportable segments in production, gathering, and its transmission segment, which is now an operated joint venture with Blackstone. All the firm's operating revenue is generated in the US, with most revenue flowing from the Marcellus Shale field and through the sale of natural gas.

Share on Social Networks: